Accretion Nutraveda made an impressive stock market debut on February 4, listing at Rs 191 per share on the BSE SME Platform, a premium of over 48 percent to its IPO price of Rs 129. The listing translated into a market capitalisation of Rs 144.80 crore for the Gujarat-based healthcare contract manufacturer.

The strong opening validates investor appetite for niche healthcare and nutraceutical manufacturing plays within the SME segment. However, the debut also revealed a subtle divergence between grey market optimism and actual exchange-based price discovery.

Ahead of listing, grey market data trackers such as Investorgain and IPO Watch indicated premiums in the range of 52–54 percent over the IPO price. The actual listing, while robust, came in below those informal expectations, underlining how grey market pricing is increasingly running ahead of fundamentals and formal demand signals in SME offerings.

Accretion Nutraveda had launched its IPO in late January to raise Rs 24.7 crore through a fully fresh issue of 19.2 lakh shares in the price band of Rs 122–129. The company operates as a contract manufacturer in the ayurvedic and nutraceutical products segment, catering to healthcare-focused clients.

The issue saw moderate but healthy participation, with overall subscription at 1.77 times between January 28 and 30. Retail investors showed stronger interest, subscribing 2.19 times their portion. Non-institutional investors subscribed 1.8 times, while the QIB portion saw marginal coverage at 1.01 times.

The minimum application size of roughly Rs 2.44 lakh positioned the IPO squarely in the high-ticket SME category, typically dominated by informed retail and HNI participation rather than broad-based institutional flows.

The listing performance reinforces an ongoing trend in SME markets where relatively small fundraises in niche, scalable segments are witnessing sharp listing gains. In Accretion Nutraveda’s case, the narrative of healthcare manufacturing, automation-led capacity expansion, and working capital support from IPO proceeds played well with investors.

The company has stated that the funds will be used for purchase of machinery to automate its existing manufacturing facility, meet working capital requirements, and for general corporate purposes. This indicates a capacity and efficiency expansion rather than diversification into unrelated segments.

The listing also reflects how SME investors are rewarding asset-light manufacturing businesses linked to structural consumption themes such as wellness, ayurveda, and nutraceutical demand.

For the SME IPO ecosystem, this listing offers two important signals.

First, investor interest remains intact for healthcare and wellness-linked manufacturing plays, even when the broader IPO market is witnessing selective participation. The theme of nutraceuticals and ayurvedic products sits at the intersection of preventive healthcare, rising disposable incomes, and export potential.

Second, the gap between grey market premiums and actual listing prices is becoming more visible. While grey markets indicated a premium exceeding 52 percent, the exchange-driven price settled lower, though still strong. This indicates that while sentiment is positive, formal price discovery is showing slightly more restraint than informal trading circles.